Metastatik kolon kanserli hastalarda serum VEGF, semaforin düzeyleri ve neuropilin-1 ekspresyonlarının prognozla ilişkisi
Yükleniyor...
Dosyalar
Tarih
2018
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Kolorektal kanser yaygın ve öldürücü bir hastalıktır. Tedavide ilerlemelere rağmen prognozu belirlemek için belirteçlere ihtiyaç vardır. Bu çalışmada metastatik kolon kanserli hastalarda serum VEGF, semaforin düzeyleri ve neurofilin-1 ekspresyonunun prognostik faktör olarak kullanımını irdeledik. Materyal ve Metod: Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi Tıbbi Onkoloji Kliniğimizde metastatik kolon kanseri tespit edilen 37 hastanın venöz kan örnekleri alındı ve serumlarından Semaforin 3A ve VEGF-A düzeyleri tedavi öncesi, 1. ay ve 3. ayda çalışıldı. Çalışmaya katılan bireylerin 19 tanesinin patoloji preperatlarında neuropilin-1 ekspresyonu bakıldı. İstatistiki yöntem olarak sağkalım analizi için Kaplan-Meier yöntemi ve prognostik faktörlerin sağkalımla ilişkisini değerlendirmek için Cox regresyon analizi kullanıldı. Bulgular: Değerlendirmeye alınan 37 hastanın yaş ortaması 60 idi. Tedavi öncesi VEGF-A düzeyi ve neuropilin-1 ekspresyonu ile sağkalım arasında anlamlı ilişki yoktu(p=0.064, p=0.344). Tedavi öncesi semaforin 3A düzeyi 5.4' den düşük olanlarda sağkalım ortalama 10.5 ay iken 5.4' den yüksek olanlarda 4.5 ay idi ve aradaki fark istatistiki olarak anlamlı idi(RO 0.23, %95 GA 9.635-11.391, p=0.012)(Karaciğer metastazı bulunması ile progresyonsuz sağkalım arasında anlamlı ilişki tespit edildi(p=0,017). Sonuç: Metastatik kolorektal kanserli hastalarda tanı anında semaforin 3A düzeyleri genel sağkalım için prognostik belirteç olarak kullanılabilir
Colorectal cancer is a common and fatal disease. Despite the progress in treatment, markers are needed to determine the prognosis. In this study, we evaluated the use of serum VEGF, semaphorin levels and neuropilin-1 expressions as prognostic factors in patients with metastatic colon cancer. Materials and Method: The study was conducted at Necmettin Erbakan Üniversitesi, Meram Medical Faculty Medical Oncology Clinic. Venous blood samples of 37 patients with metastatic colon cancer were taken, and serum semaphorin 3A and VEGF-A levels were studied in pre-treatment and the 1st and third months after the treatment was initiated. Neuropilin-1 expressions of 19 of the participated individuals were assessed in the pathology preparates. For the statistical analysis, Kaplan-Meier method was used to assess the survival analysis and Cox regression analysis was used to evaluate the association between the prognostic factors and the survival. Findings: The mean age of the 37 patients who were assessed was 60 years. There was no significant correlation between the survival and pre-treatment VEGF-A level and neuropilin-1 expression. (p=0.064, p=0.344 respectively). In patients with pre-treatment semaphorin 3A levels below 5.4, mean survival was 10.5 months and 4.5 months in patients with higher than 5.4 and the difference was statistically significant (HR 0.23, %95 CI 19.635-11391, p=0,012). There was a significant correlation between the presence of liver metastasis and progression-free survival (p=0,017). Result: In patients with metastatic colorectal cancer, semaphorin 3A levels at the time of the diagnosis can be used as a prognostic marker for the overall survival.
Colorectal cancer is a common and fatal disease. Despite the progress in treatment, markers are needed to determine the prognosis. In this study, we evaluated the use of serum VEGF, semaphorin levels and neuropilin-1 expressions as prognostic factors in patients with metastatic colon cancer. Materials and Method: The study was conducted at Necmettin Erbakan Üniversitesi, Meram Medical Faculty Medical Oncology Clinic. Venous blood samples of 37 patients with metastatic colon cancer were taken, and serum semaphorin 3A and VEGF-A levels were studied in pre-treatment and the 1st and third months after the treatment was initiated. Neuropilin-1 expressions of 19 of the participated individuals were assessed in the pathology preparates. For the statistical analysis, Kaplan-Meier method was used to assess the survival analysis and Cox regression analysis was used to evaluate the association between the prognostic factors and the survival. Findings: The mean age of the 37 patients who were assessed was 60 years. There was no significant correlation between the survival and pre-treatment VEGF-A level and neuropilin-1 expression. (p=0.064, p=0.344 respectively). In patients with pre-treatment semaphorin 3A levels below 5.4, mean survival was 10.5 months and 4.5 months in patients with higher than 5.4 and the difference was statistically significant (HR 0.23, %95 CI 19.635-11391, p=0,012). There was a significant correlation between the presence of liver metastasis and progression-free survival (p=0,017). Result: In patients with metastatic colorectal cancer, semaphorin 3A levels at the time of the diagnosis can be used as a prognostic marker for the overall survival.
Açıklama
Anahtar Kelimeler
Kolon neoplazmları, Colonic neoplasms, Neoplazm metastazları, Neoplasm metastasis, Neuropilin-1, Neuropilin-1
Kaynak
WoS Q Değeri
Scopus Q Değeri
Cilt
Sayı
Künye
Karpuz, T. (2018). Metastatik kolon kanserli hastalarda serum VEGF, semaforin düzeyleri ve neuropilin-1 ekspresyonlarının prognozla ilişkisi. (Yayınlanmamış tıpta uzmanlık tezi) Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi Dahili Tıp Bilimleri İç Hastalıklar Anabilim Dalı, Konya.
